Incyte (WBO:INCY) Accumulated Depreciation : €-248 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Incyte Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Incyte's quarterly accumulated depreciation increased from Jun. 2023 (€-221 Mil) to Sep. 2023 (€-237 Mil) and increased from Sep. 2023 (€-237 Mil) to Dec. 2023 (€-248 Mil).

Incyte's annual accumulated depreciation increased from Dec. 2021 (€-156 Mil) to Dec. 2022 (€-201 Mil) and increased from Dec. 2022 (€-201 Mil) to Dec. 2023 (€-248 Mil).

Incyte Accumulated Depreciation Historical Data

The historical data trend for Incyte's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Accumulated Depreciation Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

Get a 7-Day Free Trial

-109.68

-118.68

-155.51

-200.90

-247.53

Incyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accumulated Depreciation	Get a 7-Day Free Trial															-200.90	-210.78	-220.73	-237.31	-247.53

Incyte Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Incyte Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Incyte's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (WBO:INCY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (WBO:INCY) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

INCY:USA 1INCY:Italy ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.